Vanessa Samouelian
Overview
Explore the profile of Vanessa Samouelian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1074
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Legault E, Ribeiro P, Moreau-Amaru D, Robert E, Forte S, Comtois A, et al.
Curr Oncol
. 2025 Jan;
32(1).
PMID: 39851971
Patients with endometrial neoplasia (EN) often have multiple comorbidities and a higher surgical risk. Prehabilitation programs (PPs) combine various interventions to improve preoperative conditions and reduce impairment due to surgical...
2.
Oaknin A, Monk B, de Melo A, Kim H, Kim Y, Lisyanskaya A, et al.
Eur J Cancer
. 2025 Jan;
216:115146.
PMID: 39798514
Aim: Cemiplimab has demonstrated significantly longer survival than physician's choice of chemotherapy in patients with recurrent cervical cancer after first-line platinum-containing chemotherapy. We report the final survival analysis from the...
3.
Benoit M, Sylvestre M, Datta G, Gilbert L, Ho V, Karp I, et al.
Gynecol Oncol Rep
. 2024 Nov;
56:101540.
PMID: 39554379
Objective: To describe characteristics of sleep (quality, duration, efficiency, and insomnia) in a cohort of high-grade epithelial ovarian cancer (EOC) survivors who have completed and responded to first-line chemotherapy, and...
4.
Lambert S, Soldera S, Kazdan J, Frati F, Slominska A, Boutin M, et al.
JNCI Cancer Spectr
. 2024 Oct;
8(6).
PMID: 39468738
Background: Monitoring toxicities among patients receiving immune checkpoint inhibitors using patient-reported outcome measures (PROMs) is relatively recent. This scoping review aims to guide decision making in the development of PROMs...
5.
Kwon J, McTaggart-Cowan H, Ferguson S, Samouelian V, Lambaudie E, Guyon F, et al.
J Gynecol Oncol
. 2024 Oct;
35(6):e117.
PMID: 39453395
Objective: SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for...
6.
Slomovitz B, Cibula D, Lv W, Ortac F, Hietanen S, Backes F, et al.
J Clin Oncol
. 2024 Oct;
43(3):251-259.
PMID: 39411812
Mismatch repair-deficient (dMMR) endometrial cancer (EC) is an inflamed phenotype with poor outcomes when meeting high-risk criteria and limited treatment options in the adjuvant setting. We report protocol-prespecified subgroup analysis...
7.
Touhami O, de Guerke L, Teo Fortin L, Foo J, Provencher D, Samouelian V, et al.
Gynecol Oncol Rep
. 2024 Oct;
56:101512.
PMID: 39386924
Objective: We assessed the global distribution and academic, administrative and research outcomes of international fellows (IFs) trained in Canadian gynecologic oncology (GO) programs. Methods: A web-based survey was sent to...
8.
Ferguson S, Brotto L, Kwon J, Samouelian V, Ferron G, Maulard A, et al.
J Clin Oncol
. 2024 Oct;
43(2):167-179.
PMID: 39353164
Purpose: Simple hysterectomy and pelvic node assessment (SHAPE) is a phase III randomized trial (ClinicalTrials.gov identifier: NCT01658930) reporting noninferiority of simple compared with radical hysterectomy for oncologic outcomes in low-risk...
9.
Bernard L, Pond G, Elit L, Vicus D, Piedimonte S, Nelson G, et al.
Eur J Surg Oncol
. 2024 Aug;
50(10):108518.
PMID: 39116514
Objective: Abdominal Radical hysterectomy (ARH) with pelvic lymph node assessment is considered the standard treatment for early-stage cervical cancer. Accepted routes have previously included laparoscopic or robotic approaches (LRH). Laparoscopy-assisted...
10.
Patel M, Johnson M, Winer I, Arkenau H, Cook N, Samouelian V, et al.
Cancer Immunol Immunother
. 2024 Mar;
73(5):89.
PMID: 38554156
Background: Ezabenlimab (BI 754091) is a humanised monoclonal antibody targeting programmed cell death protein-1. We report results from open-label, dose-escalation/expansion, Phase I trials that evaluated the safety, maximum tolerated dose...